Roche’s Kadcyla Delayed In Japan And Simeprevir Gets First Market Nod In New Chuikyo Price Listings
This article was originally published in PharmAsia News
Japan subsidiary Chugai will launch clinical trials in January to provide patients access to Kadcyla while the company renegotiates the reimbursement price for the antibody drug conjugate.
You may also be interested in...
Perjeta’s approval in neoadjuvant breast cancer signals paradigm change as first approval under new pathway. Meanwhile, antibody-drug conjugate Kadcyla proves its worth in heavily pretreated, advanced breast cancer.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.